6.1 Blood Group Genetics & Molecular Inheritance

Blood Group Genetics & Molecular Inheritance

Quick Answer: Blood group antigens are inherited as Mendelian traits controlled by genes at fixed chromosomal loci, most encoding glycosyltransferases or membrane proteins rather than the antigens themselves. SBB-level practice requires fluency in codominant and amorphic inheritance, silent (null) alleles, cis-inheritance exceptions like cis-AB, and the molecular platforms (PCR-SSP, PCR-RFLP, multiplex bead arrays, and sequencing) that reference laboratories use to resolve serologic discrepancies, genotype chronically transfused patients, and predict fetal RhD status.

At the technologist level, blood banking is largely procedural. At the specialist level, the ASCP BOC content guideline expects you to reason from the underlying genetics: why a discrepancy exists, whether a variant allele explains it, and which molecular test resolves it. Nearly every advanced serologic problem you will see on the SBB exam — an unexpected ABO reverse reaction, a donor whose D typing 'looks weak,' an antibody panel that will not resolve cleanly — traces back to a gene, an allele, or a regulatory sequence.

Genotype, Phenotype, and Inheritance Patterns

Blood group genes follow classic autosomal inheritance, but the vocabulary specialists use is more precise than an introductory genetics course:

• Codominant alleles — Both alleles are expressed simultaneously with no masking. ABO's A and B alleles are the textbook example: an A/B heterozygote types as AB, not A or B, because both glycosyltransferases are produced and both antigens appear on the red cell.
• Amorphic (silent) alleles — An allele that produces no detectable antigen because the gene product is absent, non-functional, or never reaches the membrane. The common O allele of ABO is amorphic: a single-nucleotide deletion in exon 6 causes a frameshift that truncates the glycosyltransferase before its catalytic domain, so no A or B antigen forms. The classic Rh 'd' is not a true allele at all — it represents deletion or inactivation of RHD, so 'd' simply means 'no functional RHD gene product.'
• Dosage effect — Antigens with an antithetical partner (systems covered in later chapters, such as Kidd and Duffy) often react more strongly by titer or antihuman globulin (AHG) phase strength when inherited homozygous (double dose) than heterozygous (single dose). Recognizing dosage helps differentiate antibody specificities during panel resolution.
• Cis-AB — A rare inheritance pattern in which a single ABO allele encodes a hybrid glycosyltransferase with both A- and B-transferase activity, so both specificities travel together on one chromosome instead of segregating independently. A cis-AB parent (genotype cisAB/O) can pass a chromosome carrying both A and B activity to a child, producing pedigrees that look impossible under ordinary ABO rules — for example, an AB parent and an O parent producing an AB child — and often unequal A/B antigen strength within one AB individual because the hybrid enzyme is less efficient than either normal transferase.

Chromosomal Loci of the Major Blood Group Genes

Notice that FUT1 (H) and FUT2 (secretor) sit close together on chromosome 19, and FUT3 (Lewis) sits on the short arm of the same chromosome — a physical arrangement that has nothing to do with their biochemical interdependence (covered in 6.2). Distinguishing physical linkage from biochemical pathway dependence is a favorite distractor on advanced exams.

Molecular Typing Platforms

Reference and specialist laboratories resolve genetics-level problems using several complementary techniques:

• PCR-RFLP (restriction fragment length polymorphism) — Amplifies a target sequence, then digests it with a restriction enzyme that only cuts one allele; fragment size on gel electrophoresis reveals genotype. Largely a legacy or teaching technique today.
• PCR-SSP (sequence-specific priming) — Uses allele-specific primers that amplify only when they match the target exactly; presence or absence of a PCR product indicates the allele. Fast and common in reference labs for single-antigen resolution, such as RHD zygosity testing.
• Multiplex bead array platforms — Commercial panels genotype dozens of clinically significant antigens (Rh, Kell, Duffy, Kidd, MNS, and others) from one sample simultaneously using bead-based hybridization and flow detection, dramatically increasing throughput for donor rare-phenotype screening.
• Sanger sequencing and next-generation sequencing (NGS) — Used when a novel or rare variant is suspected that existing probe-based panels will not detect, such as characterizing a new partial D allele or confirming a rare null phenotype at the sequence level.

Why Genotyping Matters Clinically

1. Chronically transfused patients (for example, sickle cell disease) accumulate donor red cells that mask the patient's own phenotype on routine serologic testing. DNA-based genotyping is unaffected by recent transfusion and lets the lab predict the patient's true extended phenotype to select better-matched, alloimmunization-reducing units.
2. Fetal RHD genotyping from maternal plasma (cell-free fetal DNA) allows targeted RhIG administration — a D-negative pregnant patient carrying a genotypically D-negative fetus does not need antenatal RhIG, while one carrying a D-positive fetus does.
3. Resolving serologic weak D results into molecular weak D types determines whether a patient or donor can be safely managed as Rh-positive (detailed in 6.3).
4. Rare antigen and rare donor screening at blood centers uses high-throughput genotyping to build registries of Rh-null, U-negative, or other rare-phenotype donors far faster than serial serologic testing ever could.

Genotyping is powerful but not infallible: it predicts phenotype from known reference alleles, so a truly novel silent mutation that has not yet been cataloged can produce a genotype-phenotype mismatch. Specialists must always weigh genotyping results against serologic findings, patient history, and clinical context rather than treating either method as an automatic tiebreaker — this integrative judgment is exactly what separates SBB-level reasoning from routine bench work.